

# A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

NCT05983159

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Murdoch Childrens Research Institute
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (46)

- MODULE 1
  - Adult or paediatric patient, 2 years of age or over
  - Patient has a clinical diagnosis of a slow-flow vascular malformation
  - Patient has received standard therapy for the vascular malformation or in which, in the opinion of the investigator, standard therapy is not appropriate
  - \- Note: standard therapy may include treatment with sirolimus. A minimum of 14 days since the last dose of sirolimus is required prior to starting treatment with alpelisib
- ... and 41 more (see full listing online)

### Exclusion (61)

- History of hypersensitivity to any drugs or metabolites of PI3K inhibitors or any of the excipients of alpelisib
  - Severe infection requiring intravenous antibiotics within 4 weeks prior to enrolment
  - Patient has had a major surgical procedure within 4 weeks prior to enrolment
  - Prior use of an alpha-specific PI3K inhibitor
  - History of pneumonitis or interstitial lung disease
- ... and 56 more (see full listing online)

## Locations (2 total)

---

Peter MacCallum Cancer Centre, Parkville, Victoria, Australia  
The Royal Children's Hospital, Parkville, Victoria, Australia